JNJ 64041809

Drug Profile

JNJ 64041809

Alternative Names: ADU-741; JNJ-64041809; JNJ-809

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Aduro BioTech
  • Developer Janssen Biotech
  • Class Cancer vaccines; Immunotherapies
  • Mechanism of Action Epidermal growth factor inhibitors; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Prostate cancer

Most Recent Events

  • 28 Dec 2016 Janssen Research & Development re-initiates enrolment in a phase I trial for Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in USA (NCT02625857)
  • 18 Nov 2016 Janssen Research & Development withdraws a phase II trial for Prostate cancer (Hormone refractory, Metastatic disease, Combination therapy) prior to enrolment in USA (IV) (NCT02906605)
  • 17 Nov 2016 Janssen Research & Development suspends enrolment in a phase I trial for Prostate cancer (Metastatic disease, Second-line therapy or greater, Hormone refractory) in USA (NCT02625857)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top